Contrave vs. Wegovy Which is Better?

Contrave and Wegovy are weight loss medications that can significantly aid in weight management when used in conjunction with lifestyle changes.

In this article we will explain:

• The specifics of Contrave and Wegovy

• Their differences

• Recommended dosages and side effects

• Guidance on selecting the right option.

What is Contrave?

What is Wegovy?

If you’re currently using Mounjaro but considering a switch to Wegovy, there are important factors to consider. Learn more about the process and what to expect when switching from Mounjaro to Wegovy to ensure a smooth transition.

Wegovy vs. Contrave: What is the Difference?

• Contrave affects the brain’s reward centers to curb appetite, while Wegovy mimics a satiety-inducing gut hormone that acts on the brain to reduce appetite.

• Wegovy induces greater average weight loss than Contrave in clinical trials.

• Wegovy shows neuroprotective effects on depression, substance use disorders, and cognitive function. 

While comparing Wegovy with Contrave, it might also be helpful to understand how Wegovy stands against other medications like Rybelsus. For a detailed comparison, explore our guide on Rybelsus vs Wegovy to see which might be better suited to your needs.

Dosage for Wegovy vs. Contrave

Contrave is available as a film-coated tablet, containing 8 mg of Naltrexone and 90 mg of Bupropion. The initial dosage is one-morning tablet. During the second week an evening tablet is added, while during the third week, two tablets are taken in the morning. The maximum dose consisting of two tablets taken twice daily is reached by the fourth week.

Wegovy is available as a single-dose injection pen prefilled with one of the five different dose strengths. The starting dose of 0.25 mg once a week gradually increases every four weeks to 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg.

Dosages may vary depending on personal factors such as:

• Kidney or liver functions

Side Effects

Common side effects of Contrave and Wegovy are:

• Nausea 

• Vomiting

• Constipation

• Diarrhea

• Headache

• Dizziness

• Stomach pain.

Serious side effects possible while using either drug include:

• Serious allergic reactions

• Hypoglycemia 

• Increased heart rate.

Eating smaller low-fat meals and hydrating helps manage nausea and vomiting. 

Doctors should be informed of any concerning side effects, while emergency care is crucial for any dangerous side effects.

Is Contrave or Wegovy Better for Results?

Participants with a body mass index (BMI) of 27 or higher taking Contrave lose an average of 4.8% more weight than those given a placebo, compared to an average loss of 12.4% in those using Wegovy.

Conditions Treated

Wegovy is also beneficial for reducing the incidence of death from cardiovascular causes, heart attack, or stroke by 20%.

Drug Interactions

Contrave and Wegovy can interact with certain psychiatric medications, such as selective serotonin reuptake inhibitors which could result in serotonin syndrome.

Wegovy interacts with medications for:

• Weight management 

• Insulin/diabetes 

• Anticoagulants

• Thyroid

• Pain 

• Immunosuppression.

Contrave interacts with:

• Monoamine oxidase inhibitors

• Opioids

• Beta-blockers/type 1C antiarrhythmics

• Digoxin

• Drugs lowering the seizure threshold

• Drugs that increase dopamine.

Patients taking Contrave or Wegovy should limit/avoid alcohol.

Doctors should be consulted when considering the introduction of a new medicine.

Cost and Coverage

The price for all Wegovy dosage strengths is $388.64 per package for a 28-day supply.

The monthly cost of Contrave is $265.

Medication pricing in Canada is influenced by multiple factors including:

• Federal, provincial, and territorial governments, e.g. Ontario residents are eligible for an Ontario Health Insurance Plan (OHIP).

• Private health insurance coverage depends on the company’s policy and provider’s restrictions.

Treatment with Contrave vs Wegovy

Wegovy is proven to be effective in obese patients with mental health disorders. 

Contrave can cause mood and feeling changes and is not approved for use in psychiatric patients.

Endocrinologists and psychiatrists should analyze together the complex interaction between body weight and mental health and help choose the most appropriate treatment.

Deciding between Wegovy and other GLP-1 receptor agonists like Mounjaro can be challenging. For insights into how these two medications compare, check out our analysis of Mounjaro vs Wegovy to make an informed decision.

Key Takeaways

• Contrave is a blend of bupropion and Naltrexone in a pill taken twice a day, while Wegovy contains semaglutide administered as a weekly injection.

• Taking Contrave, as well as Wegovy, is part of a comprehensive treatment plan.

• Prescription of Contrave or Wegovy is covered by some insurance plans.

• treatment is recommended based on specific patient conditions and must be taken under medical supervision.

Frequently Asked Questions

Is Contrave Prescribed in Canada?
Yes, contrave requires a doctor’s prescription in Canada. 

What is the Sister Drug to Wegovy?
Zepbound (Tirzepatide), Trulicity (Dulaglutide), and Saxenda (Liraglutide) are alternatives =for weight management.

Can You Take Contrave and Wegovy Together?
No, because simultaneous use increases the risk of side effects. 

Sources:

• Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591.

• Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. P T. 2016 Mar;41(3):164-72. PMID: 26957883; PMCID: PMC4771085.

• Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.

• Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O’Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan;19(1):110-20. doi: 10.1038/oby.2010.147. Epub 2010 Jun 17. PMID: 20559296; PMCID: PMC4459776.

• Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. Am J Psychiatry. 2022 Dec 1;179(12):927-937. doi: 10.1176/appi.ajp.20220267. Epub 2022 Oct 26. PMID: 36285406; PMCID: PMC9722598.

• The complicated connections between weight loss drugs and mental health

• Monney M, Jornayvaz FR, Gariani K. GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes. Diabetes Metab. 2023 Sep;49(5):101470. doi: 10.1016/j.diabet.2023.101470. Epub 2023 Aug 30. PMID: 37657738.

• Laurindo LF, Barbalho SM, Guiguer EL, da Silva Soares de Souza M, de Souza GA, Fidalgo TM, Araújo AC, de Souza Gonzaga HF, de Bortoli Teixeira D, de Oliveira Silva Ullmann T, Sloan KP, Sloan LA. GLP-1a: Going beyond Traditional Use. Int J Mol Sci. 2022 Jan 10;23(2):739. doi: 10.3390/ijms23020739. PMID: 35054924; PMCID: PMC8775408.

• Chen X, Zhao P, Wang W, Guo L, Pan Q. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Am J Geriatr Psychiatry. 2024 Jan;32(1):117-127. doi: 10.1016/j.jagp.2023.08.010. Epub 2023 Aug 21. PMID: 37684186.

• Camkurt MA, Lavagnino L, Zhang XY, Teixeira AL. Liraglutide for psychiatric disorders: clinical evidence and challenges. Horm Mol Biol Clin Investig. 2018 Jul 18;36(2):/j/hmbci.2018.36.issue-2/hmbci-2018-0031/hmbci-2018-0031.xml. doi: 10.1515/hmbci-2018-0031. PMID: 30020885.

• Most GLP-1 Medications Correlated with a Lower Likelihood of Anxiety and Depression Diagnoses

• Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131.